Driving Global Health Innovations

Interview with Dr. Marcus Furch, COO, Certmedica International GmbH

Certmedica International GmbH’s headquarters in Aschaffenburg in Bavaria, Germany
Certmedica International GmbH’s headquarters in Aschaffenburg in Bavaria, Germany

Certmedica International GmbH has been an agile player in the healthcare sector since the company was founded in 2005. Headquartered in Aschaffenburg, Germany, Certmedica has steadily built a reputation for its innovative approach to metabolic health, focusing on medical conditions like obesity, cardiovascular diseases, and diabetes. Dr. Marcus Furch, who took on the role of COO in September 2023, brings a unique blend of scientific expertise and business acumen to the table. In our interview, he has shared insights into the company’s pioneering products, its international expansion, and his vision for the future.

European Business: Certmedica has often been referred to as a ‘Hidden Champion.’ What distinguishes your company in the healthcare market? 

Dr. Marcus Furch: Certmedica is a privately owned healthcare company whose mission is to improve global health through innovative, evidence-based solutions. We specialize in the development, manufacturing, and distribution of medical devices, nutritional supplements, and cosmetics. Our flagship products – formoline L112, the leading over-the-counter (OTC) anti-obesity product in Germany, and aldiamed, a moisturizer for dry mouth – are prime examples of our commitment to quality and innovation. What sets us apart is our rigorous scientific foundation. All our products are supported by clinical evidence, manufactured according to GMP or other relevant standards, and comply with the highest quality certifications, including ISO 13485 and MDR (EU Regulation 2017/745). 

Dr. Marcus Furch, COO, Certmedica International GmbH
Dr. Marcus Furch, COO, Certmedica International GmbH

We also have a strong international footprint, operating in over 40 countries through a network of specialized distributors and local partnerships. Our success is a testament to our dedication to delivering health solutions that truly make a difference. 

European Business: Let’s talk about formoline L112. What makes this product so effective for weight management?

Dr. Marcus Furch: Excess body weight and obesity are some of the most pressing health challenges of our time, affecting over 650 million people globally. They are increasingly recognized as chronic conditions which often lead to severe complications like diabetes, cardiovascular diseases, and even certain cancers. Formoline L112 addresses this challenge head-on. Its active ingredient polyglucosamine L112 is a biopolymer of natural origin that binds dietary fats in the digestive system, reducing calorie absorption. 

The My-formoline app is a class I medical device that provides users with personalized support, including diet and excercise recommendations. The app was developed in the course of 2024 and is now available in the app stores for German-speaking users
The My-formoline app is a class I medical device that provides users with personalized support, including diet and excercise recommendations. The app was developed in the course of 2024 and is now available in the app stores for German-speaking users

This process helps people lose weight and maintain their results over the long term. Clinical studies have shown remarkable outcomes: an average body weight reduction of 12 kg over 12 months, significant improvements in cholesterol and insulin levels, and a reduction in waist circumference. Unlike many alternatives, formoline L112 has no hormonal or systemic side effects, making it a safe and sustainable option. Beyond weight loss, formoline contributes to combating metabolic syndrome, which encompasses a range of conditions like high blood pressure, high cholesterol, and insulin resistance. By targeting abdominal fat – a key risk factor for men in particular – it has proven to be a vital tool for promoting metabolic health.

Formoline contributes to combating metabolic syndrome, which encompasses a range of conditions like high blood pressure or and insulin resistance
Formoline contributes to combating metabolic syndrome, which encompasses a range of conditions like high blood pressure or and insulin resistance

European Business: How is Certmedica leveraging innovation to address future health challenges?

Dr. Marcus Furch: Innovation is at the heart of everything we do. For formoline, we‘re currently conducting clinical trials to confirm its potential for preventing other conditions associated with the progression of metabolic syndrome. These studies are crucial as we aim to expand formoline’s applications and reach new patient groups. We are also currently developing a pipeline of products which support healthy aging and a long life expectancy. This includes solutions for inflammation as well as liver and intestinal health. The goal is to address chronic conditions early, enabling people to maintain their health and quality of life as they age. 

European Business: Certmedica is already active in 40 countries. What are your plans for further international expansion?

Dr. Marcus Furch: Our international strategy focuses on high-growth markets like Mexico, China, and Brazil, where we see significant potential for our products. By 2025, we want to open up new regions, including many countries in the ASEAN region following successful product approval. Partnerships are key to this growth. We work closely with specialized distributors who understand the unique needs of their local markets. This approach allows us to adapt our products and marketing strategies for maximum impact.

In-house laboratory at Magnolienweg: the heart of innovation
In-house laboratory at Magnolienweg: the heart of innovation
A laboratory test featuring the polyglucosamine L112 raw material
A laboratory test featuring the polyglucosamine L112 raw material

European Business: Digital tools seem to play an increasingly important role in Certmedica’s strategy. How do these innovations benefit your customers?

Dr. Marcus Furch: Digitization is transforming healthcare, and Certmedica is part of this shift. For example, our My-formoline app provides users with personalized support for a range of lifestyle changes, including an entertaining knowledge base and quizzes, as well as diet and exercise recommendations. This enhances treatment adherence and also empowers users to take charge of their health. We are also leveraging digital platforms for clinical research to streamline the recruitment of study participants. These ensure better compliance through features like teleconsultations and real-time tracking of patient behaviors. These tools are not only about convenience, but they represent a new way of integrating healthcare into daily life, making it more accessible and effective. Ultimately, our mission is to empower people to take control of their health, and I believe Certmedica is on a path to achieving that on a global scale.